These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 9491062)

  • 21. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
    Tollefson GD; Sanger TM
    Am J Psychiatry; 1997 Apr; 154(4):466-74. PubMed ID: 9090332
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
    Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tardive dyskinesia in affective disorders.
    Kane JM
    J Clin Psychiatry; 1999; 60 Suppl 5():43-7; discussion 48-9. PubMed ID: 10192407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olanzapine in treatment-resistant bipolar disorder.
    McElroy SL; Frye M; Denicoff K; Altshuler L; Nolen W; Kupka R; Suppes T; Keck PE; Leverich GS; Kmetz GF; Post RM
    J Affect Disord; 1998 May; 49(2):119-22. PubMed ID: 9609675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Superior efficacy of olanzapine over haloperidol: analysis of patients with schizophrenia from a multicenter international trial.
    Gomez JC; Crawford AM
    J Clin Psychiatry; 2001; 62 Suppl 2():6-11. PubMed ID: 11232753
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Naturalistic study of olanzapine in treatment-resistant schizophrenia and acute mania, depression and obsessional disorder.
    Ohaeri JU
    East Afr Med J; 2000 Feb; 77(2):86-92. PubMed ID: 10774081
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
    Tollefson GD; Beasley CM; Tamura RN; Tran PV; Potvin JH
    Am J Psychiatry; 1997 Sep; 154(9):1248-54. PubMed ID: 9286184
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The efficacy of a rapid-acting intramuscular formulation of olanzapine for positive symptoms.
    Jones B; Taylor CC; Meehan K
    J Clin Psychiatry; 2001; 62 Suppl 2():22-4. PubMed ID: 11232747
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative efficacy of olanzapine and haloperidol for patients with treatment-resistant schizophrenia.
    Breier A; Hamilton SH
    Biol Psychiatry; 1999 Feb; 45(4):403-11. PubMed ID: 10071708
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olanzapine and negative symptoms.
    Rosen EH
    J Clin Psychiatry; 1998 Oct; 59(10):537-8. PubMed ID: 9818636
    [No Abstract]   [Full Text] [Related]  

  • 32. Olanzapine versus haloperidol in the treatment of acute mania: clinical outcomes, health-related quality of life and work status.
    Shi L; Namjoshi MA; Zhang F; Gandhi G; Edgell ET; Tohen M; Breier A; Haro JM
    Int Clin Psychopharmacol; 2002 Sep; 17(5):227-37. PubMed ID: 12177585
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Olanzapine in the treatment of depressive disorders with psychotic symptoms].
    Adli M; Rossius W; Bauer M
    Nervenarzt; 1999 Jan; 70(1):68-71. PubMed ID: 10087520
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
    Tran PV; Tollefson GD; Sanger TM; Lu Y; Berg PH; Beasley CM
    Br J Psychiatry; 1999 Jan; 174():15-22. PubMed ID: 10211146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies for switching from conventional antipsychotic drugs or risperidone to olanzapine.
    Kinon BJ; Basson BR; Gilmore JA; Malcolm S; Stauffer VL
    J Clin Psychiatry; 2000 Nov; 61(11):833-40. PubMed ID: 11105736
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjunctive use of olanzapine in mood disorders: five case reports.
    Weisler RH; Ahearn EP; Davidson JR; Wallace CD
    Ann Clin Psychiatry; 1997 Dec; 9(4):259-62. PubMed ID: 9511951
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Use of olanzapine in non-psychotic psychiatric disorders.
    Goodnick PJ; Barrios CA
    Expert Opin Pharmacother; 2001 Apr; 2(4):667-80. PubMed ID: 11336615
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
    Conley RR; Mahmoud R
    Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
    Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
    Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Olanzapine in diverse syndromal and subsyndromal exacerbations of bipolar disorders.
    Janenawasin S; Wang PW; Lembke A; Schumacher M; Das B; Santosa CM; Mongkolcheep J; Ketter TA
    Bipolar Disord; 2002 Oct; 4(5):328-34. PubMed ID: 12479666
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.